Success Metrics

Clinical Success Rate
84.6%

Based on 11 completed trials

Completion Rate
85%(11/13)
Active Trials
7(24%)
Results Posted
64%(7 trials)
Terminated
2(7%)

Phase Distribution

Ph phase_3
5
17%
Ph phase_4
6
21%
Ph phase_1
2
7%
Ph phase_2
5
17%
Ph not_applicable
5
17%

Phase Distribution

2

Early Stage

5

Mid Stage

11

Late Stage

Phase Distribution23 total trials
Phase 1Safety & dosage
2(8.7%)
Phase 2Efficacy & side effects
5(21.7%)
Phase 3Large-scale testing
5(21.7%)
Phase 4Post-market surveillance
6(26.1%)
N/ANon-phased studies
5(21.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

7

trials recruiting

Total Trials

29

all time

Status Distribution
Active(10)
Completed(11)
Terminated(2)
Other(6)

Detailed Status

Completed11
unknown6
Active, not recruiting4
Not yet recruiting3
Recruiting3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
29
Active
7
Success Rate
84.6%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (8.7%)
Phase 25 (21.7%)
Phase 35 (21.7%)
Phase 46 (26.1%)
N/A5 (21.7%)

Trials by Status

active_not_recruiting414%
unknown621%
completed1138%
not_yet_recruiting310%
recruiting310%
terminated27%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT04325828Phase 2

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

Active Not Recruiting
NCT02531516Phase 3

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Active Not Recruiting
NCT07596212Phase 1

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

Not Yet Recruiting
NCT07653282Phase 1

Effect of GnRH Agonist in FET

Not Yet Recruiting
NCT07620067

GnRH for Luteal Support - Mechanism of Action

Recruiting
NCT01546987Phase 3

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Completed
NCT04356664Phase 2

Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

Recruiting
NCT07269392Phase 4

Dual Trigger With HCG and GnRH Agonist on Thawed Modified Natural Cycle Embryo Transfer

Not Yet Recruiting
NCT04025372Phase 2

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Active Not Recruiting
NCT04203381Not Applicable

Skeletal Health and Bone Marrow Composition Among Youth

Active Not Recruiting
NCT03867357

Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

Completed
NCT05838105Not Applicable

Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates

Unknown
NCT05484193Not Applicable

GnRH Agonist for Luteal Phase Support.

Unknown
NCT02993926

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Completed
NCT00724789

Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)

Completed
NCT03463252Phase 2

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Recruiting
NCT00079001Phase 3

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Completed
NCT04182594Phase 2

Cardiovascular Events in GnRH Agonist vs. Antagonist

Unknown
NCT01712230Not Applicable

Females, Aging, Metabolism, and Exercise

Completed
NCT02821819Phase 4

Random-start Ovarian Stimulation in Egg-donors (ROSE)

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
29